Lung cancer is the second most common and the deadliest type of cancer worldwide.
Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of …

Introduction The phase 3 PACIFIC trial established consolidation therapy with durvalumab
as standard of care for patients with unresectable, stage III NSCLC and no disease …

Management of stage III non-small cell lung cancer (NSCLC) is very challenging due to
being a group of widely heterogeneous diseases that require multidisciplinary approaches …

Abstract Introduction Stage III NSCLC is a heterogeneous disease requiring a multimodal
management approach. We conducted a real-world, global study to characterize patients …

Background Durvalumab consolidation is associated with improved survival following
concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer …

Despite the success of current therapy concepts, patients with advanced non-small-cell lung
cancer (NSCLC) still have a very poor prognosis. Therefore, biological markers are urgently …

Simple Summary This study reveals that circulating Hsp70 levels could serve as a tumor
biomarker for patients with NSCLC in advanced UICC stages. All patients in advanced tumor …

Objectives To report characteristics, treatment and overall survival (OS) trends, by stage and
pathology, of patients diagnosed with non-small cell lung cancer (NSCLC) at Leeds …

Patients with stage III lung adenocarcinoma (LUAD) have significant survival heterogeneity,
meanwhile, CD8+ T cell has a remarkable function in immunotherapy. Therefore …

Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped
according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3 years have been …